Beta-sitosterol dosage, safety and supplement forms
The four trials in the Cochrane review of beta-sitosterol for prostate symptoms used different preparations and amounts, so there is no single established effective dose. Non-glucosidic beta-sitosterol mixtures improved urinary flow and symptom scores over 4 to 26 weeks, while a pure beta-sitosterol glucoside preparation did not improve flow. Beta-sitosterol was well tolerated in those trials, but people with the rare inherited condition sitosterolaemia should avoid plant sterol supplements.
This article answers one question. For what Beta-Sitosterol is, where it comes from and its other uses, see the Beta-Sitosterol ingredient guide.
Key findings
- No single effective dose was defined; trial preparations and amounts varied.
- Non-glucosidic mixtures improved flow; a pure glucoside preparation did not.
- Withdrawal rates were similar to placebo (7.8% vs 8.0%).
- “Plant sterols” on a label may not match the tested preparations.
What the trials used
The Cochrane review pooled four double-blind trials (519 men, 4–26 weeks) (Wilt et al., 1999). Results favoured beta-sitosterol for symptom score (about −4.9 IPSS points in two trials), peak flow (+3.9 mL/s) and residual volume (−28.6 mL), without changing prostate size. One trial using a preparation containing only beta-sitosterol glucoside did not improve urinary flow, which suggests the form matters.
Evidence table
| Study or source | Population | What was tested | Main result | Limitations |
|---|---|---|---|---|
| Cochrane, 1999 | 4 RCTs; 519 men | Beta-sitosterol preparations vs placebo, 4–26 weeks | IPSS −4.9; flow +3.9 mL/s; residual −28.6 mL; no size change | Small, old, varied preparations |
| Glucoside-only trial (in review) | Men with BPH | Pure beta-sitosterol glucoside | No flow improvement | Single trial |
Doses: what each number means
| Amount | What kind of figure it is | Context |
|---|---|---|
| Varied across trials | Study dose | No single effective dose defined in the Cochrane review |
| No RDA or upper limit | Regulatory | Beta-sitosterol is not an essential nutrient |
| “Plant sterol” blend amounts | Commercial dose | May not state beta-sitosterol content or match tested forms |
A dose used in a study describes what researchers gave participants. It is not a personal recommendation, and it does not mean a lower or higher amount is safe or effective for you.
Supplement forms
- Non-glucosidic beta-sitosterol mixtures: the forms associated with improved flow in the Cochrane review.
- Beta-sitosterol glucoside (pure): did not improve flow in its trial.
- “Plant sterols” or “phytosterols”: mixtures of several sterols; beta-sitosterol content may not be stated.
- Pumpkin seed and saw palmetto products: contain some sterols but are different interventions.
Safety
- Well tolerated in trials, with withdrawal rates similar to placebo.
- People with sitosterolaemia, a rare inherited condition, should avoid sterol supplements.
- Urinary symptoms need medical assessment; supplements should not delay it.
Limitations
- Old, short trials with heterogeneous preparations.
- No long-term safety or effectiveness data for prostate outcomes.
Label checks
- Beta-sitosterol listed in milligrams, not only “plant sterols”.
- Whether the product states a glucoside-only form.
- Whether it sits inside a proprietary prostate blend.
Related: beta-sitosterol evidence review · saw palmetto vs beta-sitosterol
Frequently asked questions
What dose of beta-sitosterol works for BPH?
Trials used different preparations and amounts; no single effective dose was established.
Does the form matter?
Possibly. A pure glucoside preparation did not improve flow, while non-glucosidic mixtures did.
Is beta-sitosterol safe?
It was well tolerated in trials; people with sitosterolaemia should avoid it.
Does beta-sitosterol shrink the prostate?
No change in prostate size was seen.
How long did trials last?
Between 4 and 26 weeks.
References
- Wilt T, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 1999. PMID 10796740